Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Denileukin Diftitox-cxdl
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Citius Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.
Brand Name : Lymphir
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 29, 2023
Lead Product(s) : Denileukin Diftitox-cxdl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Citius Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : As part of the license agreement, Exelixis will have the right to use the AJICAP technology to support its aim of advancing multiple Antibody-drug Conjugates with the potential for higher efficacy and lower toxicity than currently available options.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 10, 2023
LOOKING FOR A SUPPLIER?